Dizlin Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Dizlin Pharmaceuticals is a private, pre-revenue biotech founded in 2003 (incorporated 2015) developing next-generation infusion therapies for advanced Parkinson's disease. Its lead assets, Infudopa SubC™ and Infudopa IntraV™, are stable liquid formulations of levodopa/carbidopa designed to provide continuous drug delivery, aiming to reduce debilitating 'on-off' symptoms. The company leverages academic collaborations and has entered a strategic global co-development agreement with Neuraxpharm, positioning it to advance its pipeline through partnership rather than building commercial infrastructure internally.

Parkinson's DiseaseNeurodegenerative Disorders

Technology Platform

Proprietary formulations of stable, high-concentration levodopa/carbidopa solutions (Infudopa™) designed for continuous subcutaneous (SubC) or intravenous (IntraV) infusion to treat motor fluctuations in advanced Parkinson's disease.

Opportunities

The large and growing global Parkinson's disease patient population, especially those progressing to advanced stages with motor complications, represents a significant unmet need.

The partnership with Neuraxpharm provides global reach and development resources, while the minimally invasive subcutaneous route offers a strong competitive advantage over existing invasive infusion therapies.

Risk Factors

The company faces significant clinical development and regulatory risks associated with proving the safety and efficacy of its novel formulations in pivotal trials.

Market adoption risks include competition from established advanced PD therapies and the challenge of changing clinical practice.

Execution is now dependent on the success of the Neuraxpharm partnership.

Competitive Landscape

Dizlin competes in the advanced Parkinson's disease space against intestinal levodopa infusion (AbbVie's Duodopa), subcutaneous apomorphine infusion, and deep brain stimulation. Its key differentiation is the potential for efficacy comparable to Duodopa with a less invasive, patient-friendly subcutaneous administration. It may also face future competition from other long-acting levodopa formulations in development.

More companies in Neuroscience & CNS →More companies in Sweden →